CTBP1 and cancer: Carvedilol is known to have multiple functions aside from blocking β-ARs; carvedilol possesses antioxidative and antiproliferative properties, and it directly inhibits ryanodine receptors and thus alters cellular handling of Ca2+ [18, 36–39], and both properties are proposed mechanisms of inhibiting cancer [40–42].